Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Nov;116(5):2435–2440. doi: 10.1111/j.1476-5381.1995.tb15092.x

Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels.

E J Hide 1, P Ney 1, J Piper 1, C Thiemermann 1, J R Vane 1
PMCID: PMC1909044  PMID: 8581281

Abstract

1. This study examined whether pretreatment of rabbits with infusions of prostaglandin E1 (PGE1) or prostaglandin E0 (PGE0) (which were terminated prior to the onset of ischaemia) reduce myocardial infarct size arising from coronary artery occlusion (60 min) and reperfusion (120 min). In addition, we investigated whether the observed cardioprotective effects of these two prostaglandins were due to the activation of ATP-sensitive potassium (KATP) channels. 2. In the anaesthetized rabbit, infarct size (expressed as a percentage of the area at risk) after 60 min of coronary artery occlusion followed by 2 h of reperfusion was 59 +/- 4% (n = 10). PGE1 or PGE0 treatment (1.0 micrograms kg-1 min-1), administered as 1 h pretreatments (0.05 ml min-1, i.v.), significantly reduced infarct size to 44 +/- 6% (n = 6) or 42 +/- 1% (n = 6), respectively. PGE1 or PGE0 pretreatment resulted in a significant reduction in mean arterial blood pressure, which returned to baseline within 15 min of discontinuation of the infusion (i.e. prior to LAL ligation). 3. The reduction in infarct size afforded by PGE1 was abolished by pretreatment of rabbits with the KATP channel blockers, glibenclamide (60 +/- 4%; n = 8) or 5-hydroxydecanoate (58 +/- 6%; n = 6). Similarly, glibenclamide also largely attenuated the reduction in infarct size afforded by PGE0 (52 +/- 3%; n = 8). 4. We propose that a 1 h pretreatment of PGE1 or PGE0 reduces infarct size by activating protein kinase C resulting in the opening of KATP channels.

Full text

PDF
2435

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araki H., Lefer A. M. Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart. Circ Res. 1980 Nov;47(5):757–763. doi: 10.1161/01.res.47.5.757. [DOI] [PubMed] [Google Scholar]
  2. Auchampach J. A., Grover G. J., Gross G. J. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res. 1992 Nov;26(11):1054–1062. doi: 10.1093/cvr/26.11.1054. [DOI] [PubMed] [Google Scholar]
  3. Auchampach J. A., Maruyama M., Cavero I., Gross G. J. The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther. 1991 Dec;259(3):961–967. [PubMed] [Google Scholar]
  4. Baller D., Bretschneider H. J., Hellige G. A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res Cardiol. 1981 Mar-Apr;76(2):163–181. doi: 10.1007/BF01907955. [DOI] [PubMed] [Google Scholar]
  5. Bouchard J. F., Dumont E., Lamontagne D. Evidence that prostaglandins I2, E2, and D2 may activate ATP sensitive potassium channels in the isolated rat heart. Cardiovasc Res. 1994 Jun;28(6):901–905. doi: 10.1093/cvr/28.6.901. [DOI] [PubMed] [Google Scholar]
  6. Cohen M. V., Liu G. S., Downey J. M. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits. Circulation. 1991 Jul;84(1):341–349. doi: 10.1161/01.cir.84.1.341. [DOI] [PubMed] [Google Scholar]
  7. Ferreira S. H., Vane J. R. Prostaglandins: their disappearance from and release into the circulation. Nature. 1967 Dec 2;216(5118):868–873. doi: 10.1038/216868a0. [DOI] [PubMed] [Google Scholar]
  8. Flores N. A., Davies R. L., Penny W. J., Sheridan D. J. Coronary microangiography in the guinea pig, rabbit and ferret. Int J Cardiol. 1984 Oct;6(4):459–471. doi: 10.1016/0167-5273(84)90326-7. [DOI] [PubMed] [Google Scholar]
  9. Grover G. J., Dzwonczyk S., Parham C. S., Sleph P. G. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drugs Ther. 1990 Apr;4(2):465–474. doi: 10.1007/BF01857755. [DOI] [PubMed] [Google Scholar]
  10. Grover G. J., McCullough J. R., Henry D. E., Conder M. L., Sleph P. G. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. J Pharmacol Exp Ther. 1989 Oct;251(1):98–104. [PubMed] [Google Scholar]
  11. Grover G. J., Sleph P. G., Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. Circulation. 1992 Oct;86(4):1310–1316. doi: 10.1161/01.cir.86.4.1310. [DOI] [PubMed] [Google Scholar]
  12. Hutton I., Parratt J. R., Lawrie T. D. Cardiovascular effects of prostaglandin E 1 in experimental myocardial infarction. Cardiovasc Res. 1973 Mar;7(2):149–155. doi: 10.1093/cvr/7.2.149. [DOI] [PubMed] [Google Scholar]
  13. Jackson W. F., König A., Dambacher T., Busse R. Prostacyclin-induced vasodilation in rabbit heart is mediated by ATP-sensitive potassium channels. Am J Physiol. 1993 Jan;264(1 Pt 2):H238–H243. doi: 10.1152/ajpheart.1993.264.1.H238. [DOI] [PubMed] [Google Scholar]
  14. Jugdutt B. I., Hutchins G. M., Bulkley B. H., Becker L. C. Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res. 1981 Sep;49(3):685–700. doi: 10.1161/01.res.49.3.685. [DOI] [PubMed] [Google Scholar]
  15. Lefer A. M., Ogletree M. L., Smith J. B., Silver M. J., Nicolaou K. C., Barnette W. E., Gasic G. P. Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science. 1978 Apr 7;200(4337):52–54. doi: 10.1126/science.345441. [DOI] [PubMed] [Google Scholar]
  16. Li G. C., Vasquez J. A., Gallagher K. P., Lucchesi B. R. Myocardial protection with preconditioning. Circulation. 1990 Aug;82(2):609–619. doi: 10.1161/01.cir.82.2.609. [DOI] [PubMed] [Google Scholar]
  17. Li Y., Kloner R. A. Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids. Cardiovasc Res. 1992 Mar;26(3):226–231. doi: 10.1093/cvr/26.3.226. [DOI] [PubMed] [Google Scholar]
  18. Lindner V., Heinle H. Binding properties of circulating Evans blue in rabbits as determined by disc electrophoresis. Atherosclerosis. 1982 Jun;43(2-3):417–422. doi: 10.1016/0021-9150(82)90040-5. [DOI] [PubMed] [Google Scholar]
  19. Liu G. S., Thornton J., Van Winkle D. M., Stanley A. W., Olsson R. A., Downey J. M. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991 Jul;84(1):350–356. doi: 10.1161/01.cir.84.1.350. [DOI] [PubMed] [Google Scholar]
  20. Lopaschuk G. D., Michalak M., Wandler E. L., Lerner R. W., Piscione T. D., Coceani F., Olley P. M. Prostaglandin E receptors in cardiac sarcolemma. Identification and coupling to adenylate cyclase. Circ Res. 1989 Sep;65(3):538–545. doi: 10.1161/01.res.65.3.538. [DOI] [PubMed] [Google Scholar]
  21. Maxwell M. P., Hearse D. J., Yellon D. M. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res. 1987 Oct;21(10):737–746. doi: 10.1093/cvr/21.10.737. [DOI] [PubMed] [Google Scholar]
  22. McCullough J. R., Normandin D. E., Conder M. L., Sleph P. G., Dzwonczyk S., Grover G. J. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res. 1991 Oct;69(4):949–958. doi: 10.1161/01.res.69.4.949. [DOI] [PubMed] [Google Scholar]
  23. McMurdo L., Thiemermann C., Vane J. R. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol. 1994 May;112(1):75–80. doi: 10.1111/j.1476-5381.1994.tb13032.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Murry C. E., Jennings R. B., Reimer K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124–1136. doi: 10.1161/01.cir.74.5.1124. [DOI] [PubMed] [Google Scholar]
  25. NACHLAS M. M., SHNITKA T. K. Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. Am J Pathol. 1963 Apr;42:379–405. [PMC free article] [PubMed] [Google Scholar]
  26. Ney P., Feelisch M. Vasodilator effects of PGE1 in the coronary and systemic circulation of the rat are mediated by ATP-sensitive potassium (K+) channels. Agents Actions Suppl. 1995;45:71–76. doi: 10.1007/978-3-0348-7346-8_11. [DOI] [PubMed] [Google Scholar]
  27. Notsu T., Tanaka I., Takano M., Noma A. Blockade of the ATP-sensitive K+ channel by 5-hydroxydecanoate in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1992 Feb;260(2):702–708. [PubMed] [Google Scholar]
  28. Pang C. Y., Forrest C. R., Mounsey R. Pharmacologic intervention in ischemia-induced reperfusion injury in the skeletal muscle. Microsurgery. 1993;14(3):176–182. doi: 10.1002/micr.1920140308. [DOI] [PubMed] [Google Scholar]
  29. Pang C. Y., Yang R. Z., Zhong A., Xu N., Boyd B., Forrest C. R. Acute ischaemic preconditioning protects against skeletal muscle infarction in the pig. Cardiovasc Res. 1995 Jun;29(6):782–788. [PubMed] [Google Scholar]
  30. Riemersma R. A., Talbot R. C., Ungar A., Mjøs O. D., Oliver M. F. Effects of prostaglandin-E1 on ST segment elevation and regional myocardial blood flow during experimental myocardial ischaemia in dogs. Eur J Clin Invest. 1977 Dec;7(6):515–521. doi: 10.1111/j.1365-2362.1977.tb01645.x. [DOI] [PubMed] [Google Scholar]
  31. Schott R. J., Rohmann S., Braun E. R., Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res. 1990 Apr;66(4):1133–1142. doi: 10.1161/01.res.66.4.1133. [DOI] [PubMed] [Google Scholar]
  32. Schrör K., Addicks K., Darius H., Ohlendorf R., Rösen P. PGI2 inhibits ischemia-induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator. Thromb Res. 1981 Jan 1;21(1-2):175–180. doi: 10.1016/0049-3848(84)90046-x. [DOI] [PubMed] [Google Scholar]
  33. Schrör K., Thiemermann C., Ney P. Protection of the ischemic myocardium from reperfusion injury by prostaglandin E1 inhibition of ischemia-induced neutrophil activation. Naunyn Schmiedebergs Arch Pharmacol. 1988 Sep;338(3):268–274. doi: 10.1007/BF00173399. [DOI] [PubMed] [Google Scholar]
  34. Simpson P. J., Mickelson J., Fantone J. C., Gallagher K. P., Lucchesi B. R. Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation. J Pharmacol Exp Ther. 1988 Feb;244(2):619–624. [PubMed] [Google Scholar]
  35. Thiemermann C., Thomas G. R., Vane J. R. Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion. Br J Pharmacol. 1989 Jun;97(2):401–408. doi: 10.1111/j.1476-5381.1989.tb11967.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Thornton J. D., Liu G. S., Olsson R. A., Downey J. M. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation. 1992 Feb;85(2):659–665. doi: 10.1161/01.cir.85.2.659. [DOI] [PubMed] [Google Scholar]
  37. Toombs C. F., Moore T. L., Shebuski R. J. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res. 1993 Apr;27(4):617–622. doi: 10.1093/cvr/27.4.617. [DOI] [PubMed] [Google Scholar]
  38. Vegh A., Papp J. G., Szekeres L., Parratt J. R. Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning? Cardiovasc Res. 1993 Apr;27(4):638–643. doi: 10.1093/cvr/27.4.638. [DOI] [PubMed] [Google Scholar]
  39. Walsh R. S., Tsuchida A., Daly J. J., Thornton J. D., Cohen M. V., Downey J. M. Ketamine-xylazine anaesthesia permits a KATP channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res. 1994 Sep;28(9):1337–1341. doi: 10.1093/cvr/28.9.1337. [DOI] [PubMed] [Google Scholar]
  40. Wu C. C., Thiemermann C., Vane J. R. Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat. Br J Pharmacol. 1995 Mar;114(6):1273–1281. doi: 10.1111/j.1476-5381.1995.tb13343.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES